Vor Biopharma Inc. Announces $55.6 Million Private Placement

Vor Biopharma Inc. recently disclosed in an 8-K filing with the Securities and Exchange Commission (SEC) that on December 26, 2024, the company entered into a Securities Purchase Agreement with certain investors. Under this agreement, Vor Biopharma agreed to issue and sell an aggregate of 55,871,260 shares of its common stock, along with accompanying warrants, to purchase up to 69,839,075 shares of common stock. The price per share and Common Stock Warrant was set at $0.99425, resulting in gross proceeds of approximately $55.6 million from this private placement.

The Private Placement is scheduled to close on December 30, 2024, with Stifel, Nicolaus & Company acting as the sole placement agent for the transaction. The proceeds from this offering are intended to fund the clinical and preclinical development of Vor Biopharma’s pipeline candidates and for general corporate purposes.

Furthermore, Vor Biopharma also entered into a Registration Rights Agreement with the Investors on the same day, obligating the company to file a registration statement on Form S-3 with the SEC within 30 days of the closing date to register the Shares and Warrant Shares for resale. The Company aims to have this Registration Statement declared effective within 75 days of the initial filing date.

Additionally, Vor Biopharma announced its expectation to release updated clinical data from its Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025. The net proceeds from the Private Placement are anticipated to extend the company’s cash runway through the announcement of updated data from these trials in 2025.

The securities offered through this Private Placement have not been registered under the Securities Act of 1933 and are sold in reliance on the exemption provided by Section 4(a)(2) of the Securities Act. The company emphasized that the Private Placement did not involve a public offering and was made without general solicitation or advertising.

The company also issued a press release on December 27, 2024, disclosing the details of the Private Placement. This information, including the press release, is not deemed filed for regulatory purposes and is not incorporated by reference into any future filings with the SEC.

Investors should note that forward-looking statements found in this report are subject to various risks and uncertainties, as detailed in the company’s filings with the SEC. Vor Biopharma undertakes no obligation to update these forward-looking statements, except as required by law.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vor Biopharma’s 8K filing here.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.